Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px
Financing › Details

Inscopix–Bruker: investment, 202211 acquisition €na of Inscopix by Bruker

 

Period Period 2022-11-08
Organisations Money taker Inscopix Inc.
  Group Bruker (Group)
  Money source Bruker Corporation (Nasdaq: BRKR)
  Group Bruker (Group)
Products Product miniscope (miniaturised microscopes for in-vivo animal brain imaging)
  Product 2 analytical instrument
Person Person Munch, Mark R. (Bruker Corp 201407 President Bruker MAT Group before President Bruker Nano Surfaces Business)
     

Bruker Corporation. (11/8/22). "Press Release: Bruker Announces Acquisition of Inscopix for Neuroscience Research". Mountain View, CA.

Head-Mounted Miniscopes Expand Neural Functional Imaging Capabilities


Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging. Since its founding in 2011, Inscopix's flagship miniscope systems have been deployed in over 600 research institutions and biopharma companies worldwide, empowering breakthroughs in fundamental neuroscience research and advancing the understanding of mechanisms in neurological disorders. This acquisition enhances Bruker’s strong reputation as a technology leader for in-vivo brain functional imaging with Ultima multiphoton microscopes at the cellular level and preclinical MRI systems at the organismal level.

“We are very proud of how far Inscopix has come in 10 years,” said Dr. Kunal Ghosh, Founder and CEO of Inscopix. “We’ve built an end-to-end ecosystem for neuroscience research, from reagents and streamlined workflow solutions to a full analysis pipeline. This acquisition will accelerate our mission of enabling a better understanding of the neural circuitry underpinning brain function and behavior, and to assist the development of new and better neurotherapeutics by our biopharma partners. As part of Bruker, we can take the next step in technology and new platform development for both academic and pharma customers.”

“Inscopix has created the head-mounted live-animal microscopy segment as a pioneer in enabling neuroscience research. Adding these products and services to our leading position in multiphoton microscopy allows an even greater level of coordination for scientific advancement,” added Dr. Mark R. Munch, Bruker NANO Group President. “With our high-resolution multiphoton microscopy and Inscopix’s free-moving head-mounted imaging, we can now offer a broad range of capabilities for exploring neural network function in animals. We look forward to seeing these synergies enable innovative academic and preclinical research.”

Inscopix revenue in FY 2022 is anticipated to be approximately $20-25 million. Bruker expects Inscopix to continue to grow revenues with double digit annual growth rates. Financial details of the transaction were not disclosed.


About Inscopix, Inc.

Based in Mountain View, CA, Inscopix is a private company founded in 2011 from Stanford University research that led to the invention of the miniscope. The innovation at the core of the Inscopix brain-mapping platform is the integration and miniaturization of the benchtop fluorescence microscope into a 2-gram device that can be mounted onto the head of a freely behaving animal to observe its brain activity. With over 1000 installations worldwide, these miniscopes are empowering advances in neuroscience research and preclinical research for the development of transformational therapeutics. Learn more at www.inscopix.com.


About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.


Investors:
Justin Ward
Senior Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media:
Stephen Hopkins
Content Marketing Manager
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker.com

   
Record changed: 2022-11-20

Advertisement

Picture Campus Berlin-Buch GmbH GMP Basic Course Online 650x200px

More documents for Bruker (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x300px




» top